Jason Martin Source Confirmed

OverviewAI-generated summary

Jason Martin's research focuses on the investigation of novel therapeutic agents and treatment strategies, particularly in the field of oncology. He has published extensively on TAR-200, a drug investigated for its efficacy in treating Bacillus Calmette–Guérin–unresponsive high-risk non–muscle-invasive bladder cancer. His work includes reporting outcomes from Phase IIb and Phase III clinical trials such as the SunRISe-1 and ATLAS studies, examining aspects like treatment durability, patient-reported outcomes, and the impact of specific patient populations and radiation therapy types.

In addition to his clinical research, Martin's scholarly activities extend to other areas. He has contributed to studies on the conversion of biomass to bio-ethanol, reflecting an interest in sustainable technologies. His academic pursuits also encompass educational research, including an examination of the relationship between intellectual need and undergraduate students' learning of calculus. Martin holds a h-index of 13, with 54 publications and 1,275 citations. He has received federal funding from the NSF for a CAREER award totaling $943,941, focused on dissecting the molecular regulation of plant invasion by the blast fungus Magnaporthe Oryzae.

Metrics

• h-index: 13
• Publications: 54
• Citations: 1,275